Skip Navigation



Brain Advance Access published online on October 27, 2004
Brain, doi:10.1093/brain/awh328
© 2004 by Guarantors of Brain
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
128/1/18    most recent
awh328v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bechtold, D. A.
Right arrow Articles by Smith, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bechtold, D. A.
Right arrow Articles by Smith, K. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received July 12, 2004
Revised September 10, 2004
Accepted September 27, 2004

Article

Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide

David A. Bechtold 1, Xu Yue 1, Richard M. Evans 1, Meirion Davies 1, Norman A. Gregson 1, and Kenneth J. Smith 1*

1 Department of Neuroimmunology, King's College, London, SE1 1UL, UK

* To whom correspondence should be addressed.
Kenneth J. Smith, E-mail: kenneth.smith{at}kcl.ac.uk


  Abstract

Inflammatory demyelinating neuropathies such as Guillain-Barré syndrome (GBS) and its animal model, experimental autoimmune neuritis (EAN), are typically acute monophasic diseases of the PNS that can leave affected individuals with permanent disability due primarily to axonal degeneration. The mechanisms underlying the degeneration are not understood, but we have previously shown in vitro and in vivo that axons can degenerate when exposed to the inflammatory mediator nitric oxide, and that axons can be protected by application of the sodium channel-blocking agent, flecainide. Here we examine whether flecainide administration can similarly reduce axonal degeneration in the periphery in animals with EAN. EAN was induced in Lewis rats (n = 116, in three independent trials), and rats received either flecainide (Flec) (30 mg/kg/day) or vehicle (Veh) from the onset of disease expression. Flecainide administration significantly reduced the mean (SD) scores for neurological deficit at both the peak of disease (Flec: 5.7 (2.7), Veh: 8.0 (3.6), P < 0.001) and at the termination of the trials 25-29 days post-inoculation (Flec: 2.2 (2.4), Veh: 4.2 (4.2), P < 0.001). Histological examination of the tibial nerve of EAN animals revealed that flecainide provided significant protection against axonal degeneration so that 80.0% of the normal number of axons survived in flecainide-treated rats compared with 62.8% in vehicle-treated rats (P < 0.01). These findings may indicate a novel avenue for axonal protection in GBS and other inflammatory demyelinating neuropathies.

Keywords: EAN; GBS; Guillain-Barré syndrome; neuroinflammation; axonal degeneration.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
M P T Lunn and H J Willison
Diagnosis and treatment in inflammatory neuropathies
Postgrad. Med. J., August 1, 2009; 85(1006): 437 - 446.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Neurological DisordersHome page
H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung
Review: Pathogenesis and treatment of immune-mediated neuropathies
Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M P T Lunn and H J Willison
Diagnosis and treatment in inflammatory neuropathies
J. Neurol. Neurosurg. Psychiatry, March 1, 2009; 80(3): 249 - 258.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
K. J. Smith
Axonal protection in multiple sclerosis--a particular need during remyelination?
Brain, December 1, 2006; 129(12): 3147 - 3149.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.